Eckert & Ziegler: Strong FY 2025 with Positive Outlook

FY 2025:

• Sales: €312.0 million (previous year: €295.8 million)
• adjusted EBIT: €77.7 million (previous year: €65.9 million)
• Net income: €48.8 million (previous year: €33.3 million)

Forecast 2026:

• Sales of approx. €320 million
• adjusted EBIT of approx. €80 million

Berlin, 26 March 2026. Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) set a new record in fiscal year 2025 with sales of €312.0 million. Compared to the previous year, sales rose by approximately €16 million (+5%). EBIT before special items from continuing operations (adjusted EBIT) increased by just under €12 million year-over-year to €77.7 million (+18%). Net income rose by approximately €15 million (+46%) to €48.8 million; this corresponds to earnings per share of €0.78 (previous year: €0.53, adjusted for stock split).

In the Medical segment, sales increased by €22.6 million, or 15%, to €171.3 million. The business with pharmaceutical radioisotopes remains the most important source of revenue.

The Isotope Products segment generated sales of €150.1 million, a decrease of €7.9 million (-5%) compared with the previous year. This was mainly due to a temporary shift toward lower-margin products compared with the same period last year. In addition, the cyberattack in 2025 led to project-related delays.

For the 2026 fiscal year, the Executive Board expects an adjusted EBIT of approximately €80 million. The corresponding sales forecast amounts to approximately €320 million. This forecast is based on a weighted average exchange rate of $1.20 per euro. Adjusted for currency effects and the licensing business, this corresponds to a growth of 9% in sales and 21% in earnings (adjusted EBIT).

The Executive Board and Supervisory Board will propose to the Annual General Meeting a dividend of €0.22 (previous year: €0.17, adjusted for stock split) per share entitled to dividends.

The 2025 financial statements can be found here: https://www.ezag.com/fy2025en/

About Eckert & Ziegler.
Eckert & Ziegler SE with more than 1.000 employees is a leading specialist for isotope-related components in nuclear medicine and radiation therapy. The company offers a broad range of services and products for the radiopharmaceutical industry, from early development work to contract manufacturing and distribution. Eckert & Ziegler shares (ISIN DE0005659700) are listed in the TecDAX index of Deutsche Börse.
Contributing to saving lives.

For enquiries please contact:
Eckert & Ziegler SE, Karolin Riehle, Investor Relations
Robert-Rössle-Str. 10, 13125 Berlin, Germany
Tel.: +49 (0) 30 / 94 10 84-138, karolin.riehle@ezag.de, www.ezag.com